96PD_PR - Evaluation of non-classical response by immune-modified RECIST and efficacy of atezolizumab beyond disease progression in advanced NSCLC: Results from the randomized Phase II study POPLAR

A Artal-Cortes,J Mazieres,L Fehrenbacher,A Rittmeyer,A.I Spira,K Park,C Lewanski,S Liu,M Ballinger,J Vansteenkiste

doi:10.1093/annonc/mdx091.016

96PD_PR - Evaluation of non-classical response by immune-modified RECIST and efficacy of atezolizumab beyond disease progression in advanced NSCLC: Results from the randomized Phase II study POPLAR

A Artal-Cortes, J Mazieres + Show 8 more

Open Access

https://doi.org/10.1093/annonc/mdx091.016

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Apr 1, 2017
Citations: 5	License type: publisher-specific-oa

Affiliation: Kaiser Permanente Vallejo Medical Center, Samsung Medical Center, Charing Cross Hospital, KU Leuven

#Efficacy Of Atezolizumab #Progression In NSCLC + Show 4 more

Abstract
Full-Text PDF
Similar Papers

Abstract

96PD_PR - Evaluation of non-classical response by immune-modified RECIST and efficacy of atezolizumab beyond disease progression in advanced NSCLC: Results from the randomized Phase II study POPLAR

Full Text